Psychiatric side-effects of medications: Recent developments

Advances in Psychiatric Treatment

Volumn 11, Issue 1, 2005, Pages 58-70

  Turjanski, Nora ^a   Lloyd, Geoffrey G ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LEVODOPA; LOPINAVIR PLUS RITONAVIR; MOOD STABILIZER; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AKATHISIA; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; BONE MARROW TOXICITY; CATATONIA; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; CONSCIOUSNESS DISORDER; DELIRIUM; DEPERSONALIZATION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE EXACERBATION; DROWSINESS; DRUG PENETRATION; DYSTHYMIA; EPILEPSY; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOMANIA; INSOMNIA; JEALOUS DELUSION; LETHARGY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; MOTOR DYSFUNCTION; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERSECUTORY DELUSION; PSYCHOSEXUAL DISORDER; PSYCHOSIS; RESTLESSNESS; REVIEW; SEROTONIN SYNDROME; SLEEP DISORDER; SOMNOLENCE; SUICIDAL BEHAVIOR; VISUAL HALLUCINATION; VIVID DREAM; WITHDRAWAL SYNDROME;

EID: 11444268737     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.11.1.58     Document Type: Review

References (87)

1. Aarsland, D., Larsen, J. P., Cummins, J. L., et al (1999a) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Archives of Neurology, 56, 595-601.
2. Aarsland, D., Larsen, J. P., Lim, N. G., et al (1999b) Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. Journal of Neuropsychiatry and Clinical Neuroscience 11, 392-394.
3. Adkins, J. C. & Noble, S. (1998) Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs, 55, 437-460.
4. Alciati, A., Starace, F., Scaramelli, B., et al (2001) Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? European Psychiatry, 16, 491-496.
5. Antoniou, T. & Tseng, A. L. (2002) Interactions between recreational drugs and antiretroviral agents. Annals of Pharmacotherapy, 36, 1598-1613.
6. Ashton, C. H. & Young, A. H. (1998) Drug-induced psychiatric disorders. In Davies' Textbook of Adverse Drug Reactions (5th edn) (eds D. M. Davies, R. E. Ferner & H. de Glanville), pp. 669-731. London: Chapman & Hall Medical.
7. Bannon, M. J. & Roth, R. H. (1983) Pharmacology of mesocortical dopamine neurons. Pharmacological Reviews, 35, 33-68.
8. Barber, R., Panikkar, A., McKeith, I. G. (2001) Dementia with Lewy bodies: diagnosis and management. International Journal of Geriatric Psychiatry, 16, S12-S18.
9. Bergman, J. & Lerner, V. (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clinical Neuropharmacology, 25, 107-110.
10. Besag, F. M. (2001) Behavioural effects of the new anticonvulsants. Drug Safety, 24, 513-536.
11. Bing, E. G., Burnam, M. A., Longshore, D., et al (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry, 58, 721-728.
12. British Medical Association & Royal Pharmaceutical Society of Great Britain (2004) British National Formulary. London & Wallingford: BMJ Books & Pharmaceutical Press.
13. Brown, T. M. & Stoudemiere, A. (1998) Psychiatric Side-effects of Prescription and Over the Counter Medications. Recognition and Management. Washington, DC: American Psychiatric Press.
14. Brunner, J., Parhofer, K. G., Schwandt, P., et al (2002) Cholesterol, essential fatty acids and suicide. Pharmacopsychiatry, 35, 1-5.
15. Cannas, A., Spissu, A., Floris, G. L., et al (2001) Chronic delusional hallucinatory psychosis in early-onset Parkinson's disease: drug-induced complication or sign of an idiopathic psychiatric illness? Neurological Sciences, 22, 53-54.
16. Catalan, J., Meadows, J. & Douzenis, A. (2000) The changing patterns of mental health problems in HIV infection: the view from London, UK. AIDS Care, 12, 333-341.
17. Catalan-Alonso, M. J. & Del Val, J. (2001) Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia? Revista de Neurologia, 32, 1085-1087.
18. Colebunders, R. & Verdonck, K. (1999) Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV Drugs. AIDS, 13, 869.
19. Cote, L. (1999) Depression: impact management by the patient and family. Neurology, 52 (suppl. 3), S7-S9.
20. Cummings, J. L. (1992) Depression and Parkinson's disease: a review. American Journal of Psychiatry, 149, 443-454.
21. Doder, M., Rabiner, E. A., Turjanski, N., et al (2000) Imaging serotonin HT1A binding in non depressed and depressed Parkinson's disease patients with 11C-WAY 100635 PET. Neurology, 54 (suppl. 3), A112.
22. Everall, I. P., Drummond, S. & Catalan, J. (2004) Guidelines for the Prescribing of Medication for Mental Health Disorders for People with HIV Infection (Draft) (Council Report CR127). London: Royal College of Psychiatrists. On-line only at www.rcpsych.ac.uk/publications/cr/council/cr127.doc.
23. Factor, S. A., Molho, E. S., Podskalny, G. D., et al (1995) Parkinson's disease: drug-induced psychiatric states. Advances in Neurology, 65, 115-138
24. Fernandez, H. H., Trieschmann, M. E., Burke, M. A., et al (2002) Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Journal of Clinical Psychiatry, 63, 513-515.
25. Fernandez, H. H., Trieschmann, M. E., Burke, M. A., et al (2003) Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Movement Disorders, 18, 510-514.
26. Foster, R., Olajide, D. & Everall, I. P. (2003) Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Medicine, 4, 139-144.
27. Friedman, J. H. & Factor, S. A. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Movement Disorders, 15, 201-211.
28. Garcia-Escrig, M., Bermejo-Pareja, F. & Fernanadez Ponsati, J. T. (1999) Levodopa-induced psychosis in patients with idiopathic Parkinson disease. Medicina Clinica (Barcelona), 112, 245-250.
29. Goetz, C. G., Blasucci, L. M., Leurgans, S., et al (2000) Olanzapine and clozapine. Comparative effects on motor function in hallucinating Parkinson's disease patients. Neurology, 55, 789-794.
30. Gonzalez, A. & Everall, I. P (1998) Lest we forget: neuropsychiatry and the new generation anti-HIV Drugs. AIDS, 12 2365-2367.
31. Graham, J. M., Grunewald, R. A. & Sagar, H. J. (1997) Hallucinosis in idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 63, 434-440.
32. Guberman, A. (1996) Vigabatrin. Canadian Journal of Neurological Sciences, 23, S13-S17.
33. Halliday, G. M., Blumbergs, P. C., Cotton, R. G., et al (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Research, 510, 104-107.
34. Harry, T. C., Matthews, M. & Salvary, I. (2000) Indinavir use: associated reversible hair loss and mood disturbance. International Journal of STD & AIDS, 11, 474-476.
35. Holcomb, H. H., Sternberg, D. E. & Heninger, G. R. (1983) Effects of electroconvulsive therapy on mood, parkinsonism and tardive dyskinesia in a depressed patient: ECT and dopamine systems. Biological Psychiatry, 18, 865-873.
36. Holroyd, S., Currie, L. & Wooten, G. F. (2001) Prospective study of hallucinations and delusions in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 70, 734-738.
37. James, J. S. (2000) St John's wort warning: do not combine with protease inhibitors, NNRTIs. AIDS Treatment News, Feb. 18 (337), 3-5.
38. Jellinger, K. A. (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Molecular and Chemical Neuropathology, 14, 153-197.
39. Kalviainen, R. (2001) Long-term safety of tiagabine. Epilepsia, 42 (suppl. 3), 46-48.
40. Kanner, A. M. & Rivas Nieto, J. C. (1999) Depressive disorders in epilepsy. Neurology, 53 (suppl. 2), S26-S32.
41. Karch, F. E. & Lasagna, L. (1975) Adverse drug reactions. A critical review. JAMA, 234, 1236-1241.
42. Ketter, T. A., Post, R. M. & Theodore, W. H. (1999) Positive and negative psychiatric side-effects of anti-epileptic drugs in patients with seizure disorders. Neurology, 53 (suppl. 2), S53-S67.
43. Khan, A., Faught, E., Gilliam, F., et al (1999) Acute psychotic symptoms induced by topiramate. Seizure, 8, 235-237.
44. Klein, C., Gordon, J., Pollak, L., et al (2003) Clozapine in Parkinson's disease psychosis: 5 year follow-up review. Clinical Neuropharmacology, 26, 8-11.
45. Lambert, M. V. & Robertson, M. M. (1999) Depression in epilepsy: etiology, phenomenology and treatment. Epilepsia, 40 (suppl. 10), S21-S47.
46. Lancman, M. (1999) Psychosis and peri-ictal confusional states. Neurology, 53 (suppl. 2), S33-S38.
47. Lang, J. P., Halleguen, O., Picard, A., et al (2001) Apropos of atypical melancholia with Sustiva (efavirenz). Encephale 27, 290-293.
48. Lawson, D. H. (1998) Epidemiology. In Davies' Textbook of Adverse Drug Reactions (5th edn) (eds D. M. Davies, R. E. Ferner & H. de Glanville), pp. 6-19. London: Chapman & Hall Medical.
49. Lera, G. & Zirulnik, J. (1999) Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Movement Disorders, 14, 128-131.
50. Levinson, D. F. & Devinsky, O. (1999) Psychiatric adverse events during vigabatrin therapy. Neurology, 53, 1503-1511.
51. Manson, A. J., Schrag, A. & Lees, A. J. (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology, 55, 795-799.
52. Maricle, R. A., Nutt, J. G. & Carter, J. H. (1995) Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion:preliminary findings. Movement Disorders, 10, 329-332.
53. Mayberg, H. S. & Solomon, D. H. (1995) Depression in Parkinson's disease: a biochemical and organic viewpoint. In Behavioral Neurology of Movement Disorders (eds W. J. Weiner & A. E. Lang). New York: Raven Press.
54. McKeith, I. G., Galasko, D., Kosaka, K., et al (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop. Neurology, 47, 1113-1124.
55. Melamed, E., Friedberg, G. & Zoldan, J. (1999) Psychosis. Impact on the patient and family. Neurology, 52 (suppl. 3), S14-S16.
56. Meyer, J. M., Marsh, J. & Simpson, G. (1998) Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Biological Psychiatry, 44, 791-794.
57. Mohr, E., Mendis, T., Hildebrand, K., et al (2000) Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Movement Disorders, 15, 1230-1237.
58. Nissenbaum, H., Quinn, N. P., Brown, R. G., et al (1987) Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychological Medicine, 17, 899-904.
59. Oinonen, K. A. & Mazmanian, D. (2002) To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70, 229-240.
60. Parkinson Study Group (1999) Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine, 340, 757-763.
61. Peyriere, H., Mauboussin, J.-M., Rouanet, I., et al (2001) Management of sudden psychiatric disorders related to efavirenz. AIDS, 15, 1323-1328.
62. Piscitelli, S. C., Burstein, A. H., Chaitt, D., et al (2000) Indinavir concentrations and St John's wort. Lancet, 355 547-548.
63. Puzantian, T. (2002) Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy, 22, 930-933.
64. Reading, P. J., Luce, A. K. & McKeith, I. G. (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders, 16, 1171-1174.
65. Riley, D. E. & Lang, A. E. (1993) The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology, 43, 1459-1464.
66. Sabato, S., Wesselingh, S., Fuller, A., et al (2002) Efavirenz-induced catatonia. AIDS, 16, 1841-1842.
67. Sackellares, J. C., Krauss, G., Sommerville, K. W., et al (2002) Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia, 43, 394-398.
68. Saint-Cyr, J. A., Taylor, A. E. & Nicholson, K. (1995) Behavior and the basal ganglia. In Advances in Neurology (vol. 65) (eds W. J. Weiner & A. E. Lang). New York: Raven Press.
69. Sano, M., Stern, Y., Cote, L., et al (1990) Depression in Parkinson!s disease: a biochemical model. Journal of Neuropsychiatry and Clinical Neuroscience, 2, 88-92.
70. Sanz de la Garza, C. L., Paoletti-Duarte, S., Garcia-Martin, C., et al (2001) Efavirenz-induced psychosis. AIDS, 15, 1911-1912.
71. Starkstein, S. E., Preziosi, T. J., Berthier, M. L., et al (1989) Depression and cognitive impairment in Parkinson's disease. Brain, 112, 1141-1153.
72. Stockley, I. (2002) Stockley's Drug Interactions: A Sourcebook of Interactions, Their Mechanisms, Clinical Importance and Management (6th edn). London: Pharmaceutical Press.
73. Swindells, S., Zheng, J. & Gendelman, H. E. (1999) HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. AIDS Patient Care and STDs, 13, 153-163.
74. Targum, S. D. & Abbott, J. L. (2000) Efficacy of quetiapine in Parkinson's patients with psychosis. Journal of Clinical Pharmacology, 20, 54-60.
75. Thomas, L., Trimble, M., Schmitz, B., et al (1996) Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Research, 23, 21-27.
76. Tiffani, T. & Cummings, J. L. (1998) Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs & Aging, 12, 55-74.
77. Tolosa, E. (2003) Advances in the pharmacological management of Parkinson disease. Journal of Neural Transmission. Supplementum, (64), 65-78.
78. Treisman, G. J. & Kaplan, A. I. (2002) Neurologic and psychiatric complications of antiretroviral agents. AIDS, 16, 1201-1215.
79. Trimble, M. R. (1991) Behavior and personality disturbances. In Neurology in Clinical Practice (2nd edn) (eds W. G Bradley, R. B. Daroff, G. M. Fenichel, et al), pp. 81-100. Stoneham, MA: Butterworth-Heinemann.
80. Trimble, M. R., Rusch, N., Betts, T., et al (2000) Psychiatric symptoms after therapy with new antiepileptic Drugs: psychopathological and seizure related variables. Seizure, 9, 249-254.
81. Trosch, R. M., Friedman, J. H., Lannon, M. C., et al (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Movement Disorders, 13, 377-382.
82. Tseng, A. L. & Fosy, M. M. (1999) Significant interactions with new antiretrovirals and psychotropic drugs. Annals of Pharmacotherapy, 33, 461-473.
83. Valldeoriola, F., Nobbe, F. A. & Tolosa, E. (1997) Treatment of behavioural disturbances in Parkinson's disease. Journal of Neural Transmission. Supplementum, 51, 175-204.
84. Vuilleumier, P. & Jallon, P. (1998) Epilepsy and psychiatric disorders: epidemiological data. Revue Neurologique, 154, 305-317.
85. Wolters, E. C., Kuiper, M. A., Zwaan, W. A., et al (1994) Dopaminomimetic psychosis: therapeutic strategies. In Mental Dysfunction in Parkinson's Ddisease (eds E. C. Wolters & P. Scheltens), pp. 281-284. Dordrecht: ICG Publications.
86. Wolters, E. C., Jansen, E. N. H., Tuynman-Qua, H. G., et al (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology, 47, 1085-1087.
87. Wolters, E. C. (1999) Dopaminomimetic psychosis in Parkinson's disease patients. Neurology, 52 (suppl. 3), S10-S13.